Get the Stockscreener App
10.63
0.09%
-0.0093
Translational Development Acquisition Corp stock is traded at $10.63, with a volume of 16,594.
It is down -0.09% in the last 24 hours and down -0.55% over the past month.
Translational Development Acquisition Corp is a newly organized blank check company.
See More
Previous Close:
$10.64
Open:
$10.64
24h Volume:
16,594
Relative Volume:
0.92
Market Cap:
$233.53M
Revenue:
-
Net Income/Loss:
$6.36M
P/E Ratio:
36.61
EPS:
0.2904
Net Cash Flow:
$-608.40K
1W Performance:
-0.09%
1M Performance:
-0.55%
6M Performance:
+2.12%
1Y Performance:
+3.82%
1-Day Range:
$10.64
$10.66
1-Week Range:
$10.64
$10.66
52-Week Range:
$10.19
$10.69
Translational Development Acquisition Corp Stock (TDAC) Company Profile
Name
Translational Development Acquisition Corp
Sector
Industry
Phone
(413) 204-2769
Address
52 E 83RD ST., NEW YORK
Compare TDAC vs LION, XXI, UMAC, DMII, BCSS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TDAC
Translational Development Acquisition Corp
|
10.66 | 233.53M | 0 | 6.36M | -608.40K | 0.2904 |
LION
Lionsgate Studios Corp
|
14.14 | 3.75B | 2.80B | -224.60M | -1.10M | -0.8751 |
XXI
Twenty One Capital Inc
|
7.465 | 2.65B | 0 | 4.35M | 456.40K | 0.3397 |
UMAC
Unusual Machines Inc
|
15.86 | 707.35M | 11.20M | -19.19M | -23.24M | -0.7527 |
DMII
Drugs Made In America Acquisition Ii Corp
|
10.05 | 640.19M | 0 | 4.19M | 0 | 0.065 |
BCSS
Bain Capital Gss Investment Corp
|
10.18 | 595.10M | 0 | 0 | 0 | 0.0729 |
Translational Development Acquisition Corp Stock (TDAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-21-21 | Initiated | Northland Capital | Outperform |
Translational Development Acquisition Corp Stock (TDAC) Latest News
Translational Development Acquisition Corp. (TDAC) Holds Steady Near Resistance as Trading Volume Remains MutedMcClellan Summation - newser.com
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid - The Manila Times
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer - NTB Kommunikasjon
TRIANA Biomedicines Adds Veteran Drug Developer Mohan Bala as COO Amid Molecular Glue Push - citybiz
Translational Development Acquisition Corp. Q1 2026 SEC 10-Q Filing: Financial Statements, Management Discussion, and Shareholder Deficit - Minichart
Mountain Crest Acquisition Corp. V 10-Q Q1 2026: Financials, Stockholder Info, and SPAC Operations Update - Minichart
Translational Development Acquisition Corp. 1Q 2026: Net income $1.33M, EPS $0.06— 10-Q Summary - TradingView
Translational Development Acquisition (NASDAQ: TDAC) flags going concern risk as SPAC deadline nears - Stock Titan
TDACW's Earnings Review - Tiger Brokers
Goldman Sachs (NASDAQ: TDAC) reports 6.1% position in TDAC - Stock Titan
Translational Development Acquisition Corp. 2025 Annual Report Amendment: SEC Review, Controls, and Exhibit Certifications - Minichart
Steele Bancorp Inc 2025 Annual Report: Financial Portfolio, Loan Segments, and Credit Assessments Explained - Minichart
Translational Development Acquisition : Amendment to Annual Report (Form 10-K/A) - marketscreener.com
Disclosure controls deemed ineffective in TDAC (NASDAQ: TDAC) 10-K/A - Stock Titan
TradingKey - TradingKey
What Translational (TDACW) is doing that smarter investors notice | TDACW Earnings: Translational Reports Zero Revenue, Acquisition Hunt PersistsTop Trending Breakouts - newser.com
CEA Industries Announces Board Changes: Tony McDonald Resigns, Carly E. Howard Appointed Chair - Minichart
Translational Development Acquisition Corp. 10-K/A Amendment – SEC Review, Internal Controls, and Nasdaq Listing - Minichart
Key Risks and Business Overview of a Development Stage Telemedicine and Compounding Pharmacy Company - Minichart
UCB to Acquire Candid for Up to $2.2B, Expanding Presence in TCE Antibodies for Immunology - Genetic Engineering and Biotechnology News
Translational Development (NASDAQ: TDAC) seeks up to 12 one‑month extensions - Stock Titan
IMG Pharmaceutical Co Ltd To Acquire Matsumoto Pharmaceutical Co Ltd To Strengthen Integrated Healthcare Platform - BioPharma APAC
TDACW Translational releases no quarterly earnings data as it continues its search for viable SPAC merger targets.Social Trade Signals - Xã Thanh Hà
GSK Completes Acquisition of 35Pharma for $950 Million - Voice of Healthcare
Published on: 2026-04-14 00:50:36 - baoquankhu1.vn
TDAC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Portfolio Update: Can Maywood Acquisition Corp Debt Equity Composite Units deliver consistent dividends2026 Market Trends & Accurate Intraday Trading Signals - baoquankhu1.vn
Tavia Acquisition (NASDAQ:TAVI) Trading 0.1% Higher – Here’s What Happened - Defense World
Translational Development Acquisition (NASDAQ:TDACU) Trading Up 3% – Here’s What Happened - Defense World
Growth Report: Can NTRP expand into new markets2026 Summary & Expert-Curated Trade Recommendations - baoquankhu1.vn
VION Biosciences Closes Acquisition of CTL, Strengthening Functional Immune Monitoring Capabilities - Business Wire
Is Translational (TDAC) Stock Testing Resistance | Price at $10.59, Up 0.09%Loss Prevention - Cổng thông tin điện tử tỉnh Lào Cai
DYOR PE Ratio & Valuation, Is DYOR Overvalued - Intellectia AI
Spartacus Acquisition Corp. II Warrants (TMTSW) stock price, news, quote and history - Yahoo Finance Singapore
Opendoor Technologies Inc. (OPENW) stock price, news, quote and history - Yahoo Finance UK
symbol__ Stock Quote Price and Forecast - CNN
Top 10 Organoid Companies - Genetic Engineering and Biotechnology News
Visionary plans anti-aging research hub, health centers with $20M - Stock Titan
TDAC (NASDAQ: TDAC) details 2025 SPAC results, trust balance and June 2026 deadline - Stock Titan
Translational Development Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy - NTB Kommunikasjon
Translational Development Acquisition Corp. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Stock List: Research Stocks from Around the World - GuruFocus
Tavia Acquisition Corp. (TAVI) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Rally Mode: Is Ainos Inc a play on infrastructure spendingWeekly Risk Summary & Weekly Setup with ROI Potential - baoquankhu1.vn
Market Review: Can Translational Development Acquisition Corp outperform in the next rallyChart Signals & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio - StreetInsider
TDAC Should I Buy - Intellectia AI
Geopolitics Watch: Is Tapestry Inc a defensive stock2026 Historical Comparison & Daily Chart Pattern Signals - baoquankhu1.vn
Profit Recap: Is Qiagen NV part of any major indexShare Buyback & Stepwise Trade Execution Plans - baoquankhu1.vn
NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026 - Business Wire
Translational Development Acquisition Corp Stock (TDAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):